Tuberculosis and Rifampin


Tuberculosis Symptoms and Causes

Tuberculosis (TB) is a disease caused by bacteria called Mycobacterium Tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body.

TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. If you have been exposed, you should go to your doctor for tests. You are more likely to get TB if you have a weak immune system.

Symptoms of TB in the lungs may include

  • A bad cough that lasts 3 weeks or longer
  • Weight loss
  • Loss of appetite
  • Coughing up blood or mucus
  • Weakness or fatigue
  • Fever
  • Night sweats

Skin tests, blood tests, x-rays, and other tests can tell if you have TB. If not treated properly, TB can be deadly. You can usually cure active TB by taking several medicines for a long period of time.

NIH: National Institute of Allergy and Infectious Diseases

Check out the latest treatments for tuberculosis

tuberculosis treatment research studies

Rifampin clinical trials, surveys and public health registries

Find Drug Side Effect reports

Rifampin Side Effects

Alanine Aminotransferase Increased (33)
Aspartate Aminotransferase Increased (32)
Hepatitis (27)
Pyrexia (25)
Hepatocellular Damage (24)
Nausea (23)
Renal Failure Acute (23)
Vomiting (18)
Blood Bilirubin Increased (15)
Rash (14)
Asthenia (13)
Diarrhoea (13)
Dyspnoea (13)
Thrombocytopenia (13)
Fatigue (13)
Hypotension (12)
Erythema (11)
Hepatic Failure (10)
Headache (10)
Anaemia (9)
Arthralgia (9)
Dizziness (9)
Myalgia (9)
Jaundice (9)
Confusional State (8)
Blood Alkaline Phosphatase Increased (8)
Condition Aggravated (8)
Abdominal Pain (7)
Malaise (7)
Dehydration (7)
Tubulointerstitial Nephritis (7)
Neutropenia (7)
Haemodialysis (6)
Chills (6)
Hyperhidrosis (6)
Decreased Appetite (6)
Hypertension (6)
Renal Failure (6)
Liver Disorder (6)
Anorexia (5)
Dyspepsia (5)
Coma (5)
Heart Rate Increased (5)
Oral Candidiasis (5)
Oedema Peripheral (4)
Pain (4)
Lymphadenopathy (4)
Leukopenia (4)
International Normalised Ratio Increased (4)
Liver Function Test Abnormal (4)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Tuberculosis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium TUBERCULOSIS and in Predicting Progression to TUBERCULOSIS
Conditions: Latent TUBERCULOSIS Infection;   TUBERCULOSIS Disease
Outcome Measures: Latent TUBERCULOSIS infection;   TUBERCULOSIS disease at 6 months;   TUBERCULOSIS disease at 12 months;   TUBERCULOSIS disease at 18 months;   TUBERCULOSIS disease at 24 months
2 Unknown  Surveillance and Follow-up for Latent TUBERCULOSIS Infection and Observation of the Effect of Prophylactic Latent TUBERCULOSIS Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis
Conditions: To Determine the Prevalence of Latent TUBERCULOSIS in Each Group;   To Monitor the Occurrence of Active TUBERCULOSIS
Outcome Measures: occurrence of active TUBERCULOSIS;   Latent TUBERCULOSIS infection
3 Recruiting Training Protocol on the Natural History of TUBERCULOSIS
Outcome Measures: Develop on-site NIH Clinical Center (CC)/NIAID experience in the standard of care of TUBERCULOSIS patients with drug sensitive and drug resistant disease, as well as latent TUBERCULOSIS.;   Characterize in vitro immune responses of patients with TUBERCULOSIS to a panel of agonists including but not limited to, strains of Mycobacterium TUBERCULOSIS (MTB), MTB antigens, and purified stimuli (e.g. Pam3Cys, LPS, HKLM).;   Characterize lymphoid profiles of patients with drug-sensitive (DS) TB, multi-drug resistant (MDR) TB, and extensively drug-resistant (XDR) TB both during acute, convalescent, and cured disease.
4 Recruiting Multi-Drug Resistant TUBERCULOSIS in Korea
Outcome Measure:
5 Recruiting Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary TUBERCULOSIS
Condition: Pulmonary TUBERCULOSIS
Intervention: Procedure: Diagnostic techniques in pulmonary TUBERCULOSIS
Outcome Measure: Sensibility of diagnosis of TUBERCULOSIS (positive culture and/or PCR)
6 Unknown  Intestinal TUBERCULOSIS Diagnostics and the Differentiation From Crohn's Disease
Conditions: Intestinal TUBERCULOSIS;   Pulmonary TUBERCULOSIS;   Crohn's Disease
Outcome Measures: Calprotectin levels in patients with active intestinal TUBERCULOSIS;   Levels of calprotectin in patients with intestinal TUBERCULOSIS after antituberculous therapy.
7 Unknown  Treatment Duration for Abdominal TUBERCULOSIS
Condition: Treatment Duration for Abdominal TUBERCULOSIS
Interventions: Drug: RNTCP Category I treatment for 6 months;   Drug: RNTCP Category I treatment for 9months
Outcome Measures: Response to treatment (after 6 months and nine months of RNTCP Category I treatment);   Recurrence of symptoms of abdominal TUBERCULOSIS (intestinal and peritoneal) after 1 year of follow up in those who receive 6 months or 9 months of Cat I treatment
8 Recruiting Improving Diagnosis of TUBERCULOSIS in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)
Conditions: HIV;   TUBERCULOSIS;   Pediatric
Intervention: Other: Development of a diagnosis algorithm
Outcome Measures: TUBERCULOSIS diagnosis assessment;   Evaluation of the QuantiFERON(R)-TB Gold In-Tube;   Comparison of two in-vitro IGRAs;   Percentage of TB diagnosis sampling procedures actually performed;   Evaluation of the morbidity (IRIS, drug toxicity and other opportunistic infections) and mortality in TB-HIV co-infected children;   Specificity and sensibility of TB diagnosis sampling procedures compared to TB diagnosis gold standard (sputum culture)
9 Recruiting Siemens VOC TB Pilot Study
Outcome Measures: Percentage of correctly identified patients with TUBERCULOSIS;   Change in VOC pattern induced by storage for several days;   Change in VOC pattern induced by storage temperature;   Change in VOC pattern induced by TUBERCULOSIS therapy
10 Unknown  Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary TUBERCULOSIS
Intervention: Drug: combined fixed dose combination
Outcome Measures: Efficacy : combined rate of failure at the end of treatment and relapse by 30 months.;   Safety : occurrence of serious adverse events at any time during chemotherapy;   Sputum culture results at two months of chemotherapy;   Rate of completion of chemotherapy according to the protocol
11 Recruiting Latency in Pulmonary TUBERCULOSIS
Condition: Pulmonary TUBERCULOSIS
Intervention: Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Outcome Measures: The immune response to crude antigens - PPD and CFA and defined antigens - ESAT-6 and CFP-10 as well as positive controls- SEB and anti-CD3.;   Determining the correlation of increase in regulatory factors with the development of relapse in treated TB patients.
12 Not yet recruiting Trial in Pulmonary TUBERCULOSIS Patients With Diabetes Mellitus
Conditions: Diabetes Mellitus;   Pulmonary TUBERCULOSIS
Intervention: Procedure: intensive monitoring
Outcome Measures: Better diabetes control in diabetes patients with TUBERCULOSIS under treatment;   Cost-effectiveness of different strategies for diabetes management during TB treatment;   Measurement of long-term requirements for diabetes management in TB patients diagnosed with diabetes after TB treatment completed;   Association between glycemic control and clinical-microbiological response to TB treatment
13 Recruiting Development of a Score for Differential Diagnosis Between Intestinal TUBERCULOSIS and Crohn's Disease
Conditions: Crohn's Disease;   Intestinal TUBERCULOSIS
Outcome Measure: Final diagnosis(Crohn's disease or Intestinal TUBERCULOSIS)
14 Recruiting The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent TUBERCULOSIS Infection
Conditions: Rheumatic Disease;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   TUBERCULOSIS
Outcome Measures: The agreement between QuantiFERON-TB Gold(QFT-G) and tuberculin skin test(TST) as a screening test for latent TUBERCULOSIS infection(LTBI);   The correlation of the occurrence of active TUBERCULOSIS and two tests (QuantiFERON-TB Gold (QFT-G) and TUBERCULOSIS skin test(TST))
15 Not yet recruiting Evaluation of the Pharmacokinetics of AntiTUBERCULOSIS Drugs and TUBERCULOSIS Treatment Outcomes
Intervention: Drug: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
Outcome Measures: clinical outcome;   Cmax;   Number of adverse events;   ART trough levels;   Isoniazid Cmax
16 Unknown  Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for TUBERCULOSIS
Conditions: Acquired Immunodeficiency Syndrome;   TUBERCULOSIS
Intervention: Other: Comparison of different treatment strategies
Outcome Measures: mortality;   TUBERCULOSIS-Immune Reconstitution Inflammatory Syndrome;   New AIDS defining clinical events;   Drug Induced Liver toxicity;   Virologic success
17 Recruiting Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active TUBERCULOSIS in HIV-Infected Individuals With Latent TUBERCULOSIS Infection
Conditions: TUBERCULOSIS;   HIV Infections
Interventions: Drug: Rifapentine (RPT);   Drug: Isoniazid (INH);   Dietary Supplement: Pyridoxine (Vitamin B6)
Outcome Measures: Time from randomization to first diagnosis of active TB;   Occurrence of one or more serious adverse events (SAEs) versus no SAEs;   Highest reported grade of each new Grade 3 or 4 laboratory value or sign or symptom that is at least one grade increase from baseline for targeted events;   Ordered categorical variable indicating most stringent level of study drug management due to toxicity that was required over the treatment period;   Time from randomization to death from any cause;   Time from randomization to death due to a non-TB event;   Efavirenz (EFV) plasma concentrations at Weeks 2 and 4;   Nevirapine (NVP) plasma concentrations at Weeks 2 and 4;   Adherence to TB treatment;   Antibiotic resistance pattern of Mycobacterium TUBERCULOSIS (MTB) isolates in participants who develop active TB;   HIV-1 RNA changes from baseline to Week 8;   Polymorphisms in host genes involved in metabolism or transport of EFV, NVP, and RPT;   Cost-effectiveness measures
18 Recruiting Evaluation of an Enhanced TUBERCULOSIS Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand
Intervention: Behavioral: Enhanced TB IC Package
Outcome Measures: Change in prevalence and incidence of latent TUBERCULOSIS infection in healthcare workers;   Change in institutional safety culture;   Adherence to recommended TB Infection Control practices
19 Recruiting Rapid Diagnosis of Pulmonary TUBERCULOSIS
Interventions: Drug: Salbutamol;   Drug: Sodium chloride 5%
Outcome Measures: Sputum direct smear positive for acid-fast bacilli.;   Sputum culture positive for Mycobacterium TUBERCULOSIS.
20 Recruiting Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary TUBERCULOSIS
Condition: Extrapulmonary TUBERCULOSIS
Interventions: Genetic: Genetic analysis;   Radiation: Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM;   Other: Immunologic analysis;   Other: QuantiferonTB Gold test
Outcome Measures: Risk factors of paradoxical reaction;   Incidence and natural history of paradoxical reactions;   Immune description of paradoxical reactions;   Preliminary study of Diagnosis factors of paradoxical reaction